Zealand Pharma has filed a patent for pharmaceutical compositions with specific preservatives. The claim includes a formula for GLP-1/GLP-2 dual agonists and the use of m-cresol and/or phenol as preservatives along with tris buffer. GlobalData’s report on Zealand Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Zealand Pharma, Hormone-based therapies for metabolic disorders was a key innovation area identified from patents. Zealand Pharma's grant share as of January 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
The patent application (Publication Number: US20240024425A1) discloses a composition comprising a GLP-1/GLP-2 dual agonist with a specific chemical structure, an albumin binding moiety, and a tris buffer. The composition also includes one or more preservatives, such as m-cresol and/or phenol. Additionally, the composition is formulated as an isotonic parenteral pharmaceutical composition, with the tris buffer present at a concentration ranging from about 5 mM to about 50 mM, and a pH between 6.0 to 8.5.
Furthermore, the composition may contain tonicity agents like mannitol or NaCl, with specific concentrations specified for each component. The GLP-1/GLP-2 dual agonist is present at a concentration of at least 1 mg/mL, with options for concentrations of about 2 mg/mL, 15 mg/mL, or 25 mg/mL. The preservatives m-cresol and phenol are included at defined concentrations, and the composition may also comprise chloride salts of specific GLP-1/GLP-2 dual agonists. Overall, the patent application outlines a detailed formulation for a pharmaceutical composition containing a GLP-1/GLP-2 dual agonist, preservatives, tonicity agents, and buffers, designed for parenteral administration.
To know more about GlobalData’s detailed insights on Zealand Pharma, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.